2105 Stock Overview
An investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Laekna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.71 |
| 52 Week High | HK$26.45 |
| 52 Week Low | HK$3.15 |
| Beta | 0 |
| 1 Month Change | -26.79% |
| 3 Month Change | -22.10% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2105 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -12.3% | 0.5% | -1.8% |
| 1Y | n/a | -36.9% | -3.7% |
Return vs Industry: Insufficient data to determine how 2105 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2105 performed against the Hong Kong Market.
Price Volatility
| 2105 volatility | |
|---|---|
| 2105 Average Weekly Movement | 22.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2105's share price has been volatile over the past 3 months.
Volatility Over Time: 2105's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 89 | Chris Lu | www.laekna.com |
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, and LAE120 for the treatment of cancer; LAE103 and LAE123 to treat muscle atrophy diseases; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis.
Laekna, Inc. Fundamentals Summary
| 2105 fundamental statistics | |
|---|---|
| Market cap | HK$2.23b |
| Earnings (TTM) | -HK$397.07m |
| Revenue (TTM) | HK$506.01k |
4,402x
P/S Ratio-5.6x
P/E RatioIs 2105 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2105 income statement (TTM) | |
|---|---|
| Revenue | CN¥470.00k |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥470.00k |
| Other Expenses | CN¥369.28m |
| Earnings | -CN¥368.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 100.00% |
| Net Profit Margin | -78,471.06% |
| Debt/Equity Ratio | 6.1% |
How did 2105 perform over the long term?
See historical performance and comparison